Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients with Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer
Demographics (4)
- AGE_ONSET - Disease onset age (phv00508331.v1.p1)
- COLLECTION_AGE - Age sample was collected (phv00508346.v1.p1)
- D_SEX - Sex (phv00508332.v1.p1)
- SEX - Biological sex (phv00508327.v1.p1)
Disease Events (11)
- D_CANCERTYPE - Cancer diagnosis (phv00508334.v1.p1)
- D_CANCERTYPE - Site of primary tumor (phv00508343.v1.p1)
- D_DIFFGRADE - Tumor differentiation (phv00508345.v1.p1)
- D_HISTOLOGY - Cancer histology type (phv00508335.v1.p1)
- D_HISTOLOGY - Cell or tissue type or subtype of sample (phv00508344.v1.p1)
- D_STAGEDX - Disease stage at diagnosis (phv00508336.v1.p1)
- D_STUDYTX - Treatment received on the study (phv00508337.v1.p1)
- OS - Overall survival in days (phv00508340.v1.p1)
- OS_cens - Overall survival censoring (0 = No, 1 = Yes) (phv00508341.v1.p1)
- PFS - Progression free survival in days (phv00508338.v1.p1)
- PFS_cens - Progression free survival censoring (0 = No, 1 = Yes) (phv00508339.v1.p1)
Race and Ethnicity (1)
- D_RACE - Self-reported race (phv00508333.v1.p1)
Other (8)
- ANALYTE_TYPE - Analyte Type (phv00508348.v1.p1)
- CONSENT - Consent group as determined by DAC (phv00508326.v1.p1)
- IS_TUMOR - Tumor status (phv00508347.v1.p1)
- SAMPLE_ID - Sample ID (phv00508342.v1.p1)
- SAMPLE_ID - Sample ID (phv00508329.v1.p1)
- SUBJECT_ID - Subject ID (phv00508330.v1.p1)
- SUBJECT_ID - Subject ID (phv00508325.v1.p1)
- SUBJECT_ID - Subject ID (phv00508328.v1.p1)